EMSO 2026: Incyte a ‘firm contender’ in G12D pancreatic cancer race as early candidate shines
Incyte’s KRAS G12D inhibitor achieved an 89% confirmed objective response rate in an early-stage clinical trial for a type of…
Incyte’s KRAS G12D inhibitor achieved an 89% confirmed objective response rate in an early-stage clinical trial for a type of…